Medindia LOGIN REGISTER
Medindia

Drug Safety Labeling Changes - February 2015

Food and Drug Administration (FDA) announces important safety label changes for prescription drugs almost every month. By implementing the label changes the FDA warns a physician of new side- effects, adverse reactions, contra-indications and precautions necessary for a drug. This information is important for safe practice of medicine.

Key to Label Sections

  • C - Contraindications
  • W - Warnings
  • P - Precautions
  • AR - Adverse Reactions
Drug Name Sections Modified
C W P AR
Bicalutamide - Tablets
Deferiprone - Tablets
Oxybutynin Hydrochloride - Extended Release Tablets
Alendronate - Effervescent Tablets for Oral Solution
Baclofen - Injection
Candesartan -Tablets
CISplatin - Injection, Sterile Aqueous Injection
Degarelix - for Injection Lyophilized Powder for Injection
Exenatide - Injection
Galantamine - HBr Tablets, Oral Solution
Galantamine - HBr Extended-Release Capsules
Goserelin - Implant
Lamivudine - Tablets and Oral Solution
Minocycline - Oral Suspension
Ospemifene - Oral Tablets
Pentoxifylline - 400 mg Extended-Release Tablets
Piroxicam - Capsules
Pramlintide Acetate Injection
Prazosin - Hydrochloride Capsules
Propylthiouracil - Tablets
Raltegravir - for Oral Suspension, Chewable Tablets, and Film-coated Tablets
Rivastigmine - Capsule and Oral Solution
Rivastigmine - Transdermal System
Rotigotine -Transdermal System
Temsirolimus - Injection
Voriconazole - Tablets, for Oral Suspension, and for Injection

2016 - Monthly Summary Report for Drug Label Changes

2015 - Monthly Summary Report for Drug Label Changes

2014 - Monthly Summary Report for Drug Label Changes

2013 - Monthly Summary Report for Drug Label Changes

2012 - Monthly Summary Report for Drug Label Changes

Drugs A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Get Health and Wellness Secrets from Our Engaging eBooks
Stay Connected
Available on the Android Market Available on the App Store